Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt: 2020-2022

Historic Total Debt for C4 Therapeutics (CCCC) over the last 3 years, with Dec 2022 value amounting to $11.5 million.

  • C4 Therapeutics' Total Debt fell 7.08% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year decrease of 7.08%. This contributed to the annual value of $11.5 million for FY2022, which is 6.63% up from last year.
  • C4 Therapeutics' Total Debt amounted to $11.5 million in FY2022, which was up 6.63% from $10.8 million recorded in FY2021.
  • In the past 5 years, C4 Therapeutics' Total Debt ranged from a high of $11.5 million in FY2022 and a low of $10.1 million during FY2020.
  • For the 3-year period, C4 Therapeutics' Total Debt averaged around $10.8 million, with its median value being $10.8 million (2021).
  • Data for C4 Therapeutics' Total Debt shows a peak YoY increased of 7.12% (in 2021) over the last 5 years.
  • C4 Therapeutics' Total Debt (Yearly) stood at $10.1 million in 2020, then rose by 7.12% to $10.8 million in 2021, then grew by 6.63% to $11.5 million in 2022.